Skip to main
ATOS
ATOS logo

Atossa Genetics (ATOS) Stock Forecast & Price Target

Atossa Genetics (ATOS) Analyst Ratings

Based on 6 analyst ratings
Strong Buy
Strong Buy 83%
Buy 17%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Atossa Therapeutics Inc. holds a positive outlook due to its development of Z-endoxifen, which has demonstrated broad utility and encouraging efficacy across various breast cancer treatment settings, particularly showing favorable results in both ESR1 mutant and wild-type patients. The company's strategic focus on metastatic breast cancer (mBC) reflects valuable insights gained from interactions with regulatory advisors and key opinion leaders, positioning it well within the competitive oral selective estrogen receptor degrader (SERD) landscape. Furthermore, the ongoing development of additional therapeutic candidates, including drugs for COVID-19, provides further potential for significant growth and enhances the company's overall product pipeline.

Bears say

Atossa Therapeutics faces significant risks that negatively impact its stock outlook, including potential safety issues and lower-than-expected efficacy in its clinical programs, which could hinder progress and market acceptance. Furthermore, the company needs to secure approximately $275 million in additional financing by 2037, with a cash runway extending only into the second half of 2026, raising concerns about its financial sustainability. Additionally, the risk of delisting if the share price falls below $1, combined with increased competition and regulatory challenges, compounds the overall negative sentiment surrounding the company's future prospects.

Atossa Genetics (ATOS) has been analyzed by 6 analysts, with a consensus rating of Strong Buy. 83% of analysts recommend a Strong Buy, 17% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Atossa Genetics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Atossa Genetics (ATOS) Forecast

Analysts have given Atossa Genetics (ATOS) a Strong Buy based on their latest research and market trends.

According to 6 analysts, Atossa Genetics (ATOS) has a Strong Buy consensus rating as of Jul 2, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $6.92, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $6.92, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Atossa Genetics (ATOS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.